Dupilumab in Allergic Fungal Rhinosinusitis (AFRS)

The duration of study for each participant will include 2-4 weeks of screening period, 52 weeks of randomized IMP intervention period and 12 weeks of follow-up period.

A Randomized Double-blind Placebo-controlled Parallel Group Study Assessing the Efficacy and Safety of Dupilumab in Patients With Allergic Fungal Rhinosinusitis (AFRS)

Primary Objective: To evaluate the ability of dupilumab to reduce the need for rescue therapy with systemic corticosteroids (SCS) or surgery of AFRS in patients with AFRS who previously have had surgery for AFRS Secondary Objectives: To evaluate the efficacy of treatment with dupilumab to reduce sinus opacification in a population with allergic fungal rhinosinusitis (AFRS) To assess the efficacy of dupilumab to reduce the need for rescue treatments To evaluate the efficacy of treatment with dupilumab in improving symptoms in AFRS To evaluate the efficacy of dupilumab to reduce nasal polyp formation in patients with AFRS To evaluate the efficacy of dupilumab in improving overall symptom severity and quality of life in AFRS To evaluate the efficacy of dupilumab in improving sense of smell in patients with AFRS To explore the effect of dupilumab as assessed by three-Dimensional CT volumetric measurement of the paranasal sinuses To evaluate the safety and tolerability of dupilumab when administered to patients with AFRS To evaluate the pharmacokinetics (PK) of dupilumab in patients with AFRS To characterize the effect of dupilumab on total IgE and specific IgE To assess immunogenicity to dupilumab in patients with AFRS

Dupilumab in Allergic Fungal Rhinosinusitis (AFRS)

Recruitment

Summary

Participation Requirements

Description

Tracking Information